169 related articles for article (PubMed ID: 35280017)
1. [Recurrence and metastasis of pheochromocytoma/paraganglioma after tumor resection and clinical characteristics analysis].
Gao YJ; Cui YY; Ma XS; Wang HP; Liu J; Lou FC; Zhou T; Chen S; Lu L; Tong AL
Zhonghua Yi Xue Za Zhi; 2022 Mar; 102(10):729-734. PubMed ID: 35280017
[No Abstract] [Full Text] [Related]
2. [Clinical features of patients with metastatic pheochromocytoma/paraganglioma].
Cui YY; Zhou Y; Gao YJ; Li TY; Wang Y; Zhang WQ; Zhou T; Chen S; Tong AL
Zhonghua Yi Xue Za Zhi; 2024 Apr; 104(14):1174-1179. PubMed ID: 38583049
[No Abstract] [Full Text] [Related]
3. Clinical Predictors of Malignancy in Patients with Pheochromocytoma and Paraganglioma.
Dhir M; Li W; Hogg ME; Bartlett DL; Carty SE; McCoy KL; Challinor SM; Yip L
Ann Surg Oncol; 2017 Nov; 24(12):3624-3630. PubMed ID: 28884434
[TBL] [Abstract][Full Text] [Related]
4. Clinical Presentation and Treatment Outcomes of Children and Adolescents With Pheochromocytoma and Paraganglioma in a Single Center in Korea.
Park H; Kim MS; Lee J; Kim JH; Jeong BC; Lee S; Lee SK; Cho SY; Jin DK
Front Endocrinol (Lausanne); 2020; 11():610746. PubMed ID: 33584544
[TBL] [Abstract][Full Text] [Related]
5. Recurrent Disease in Patients With Sporadic Pheochromocytoma and Paraganglioma.
Li M; Prodanov T; Meuter L; Kerstens MN; Bechmann N; Prejbisz A; Remde H; Timmers HJLM; Nölting S; Talvacchio S; Berends AMA; Fliedner S; Robledo M; Lenders JWM; Pacak K; Eisenhofer G; Pamporaki C
J Clin Endocrinol Metab; 2023 Jan; 108(2):397-404. PubMed ID: 36190922
[TBL] [Abstract][Full Text] [Related]
6. Local-Regional Recurrence of Pheochromocytoma/Paraganglioma: Characteristics, Risk Factors and Outcomes.
Cui Y; Ma X; Gao Y; Chang X; Chen S; Lu L; Tong A
Front Endocrinol (Lausanne); 2021; 12():762548. PubMed ID: 34899602
[TBL] [Abstract][Full Text] [Related]
7. Predictors of recurrence of pheochromocytoma and paraganglioma: a multicenter study in Piedmont, Italy.
Parasiliti-Caprino M; Lucatello B; Lopez C; Burrello J; Maletta F; Mistrangelo M; Migliore E; Tassone F; La Grotta A; Pia A; Reimondo G; Giordano R; Giraudo G; Piovesan A; Ciccone G; Deandreis D; Limone P; Orlandi F; Borretta G; Volante M; Mulatero P; Papotti M; Aimaretti G; Terzolo M; Morino M; Pasini B; Veglio F; Ghigo E; Arvat E; Maccario M
Hypertens Res; 2020 Jun; 43(6):500-510. PubMed ID: 31586159
[TBL] [Abstract][Full Text] [Related]
8. Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems.
Wachtel H; Hutchens T; Baraban E; Schwartz LE; Montone K; Baloch Z; LiVolsi V; Krumeich L; Fraker DL; Nathanson KL; Cohen DL; Fishbein L
J Clin Endocrinol Metab; 2020 Dec; 105(12):e4661-70. PubMed ID: 32877928
[TBL] [Abstract][Full Text] [Related]
9. Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years.
Hamidi O; Young WF; Iñiguez-Ariza NM; Kittah NE; Gruber L; Bancos C; Tamhane S; Bancos I
J Clin Endocrinol Metab; 2017 Sep; 102(9):3296-3305. PubMed ID: 28605453
[TBL] [Abstract][Full Text] [Related]
10. Paraganglioma: not just an extra-adrenal pheochromocytoma.
Laird AM; Gauger PG; Doherty GM; Miller BS
Langenbecks Arch Surg; 2012 Feb; 397(2):247-53. PubMed ID: 22086065
[TBL] [Abstract][Full Text] [Related]
11. A 15-year pheochromocytoma and paraganglioma experience in a single centre: a Singapore perspective.
Lee Y; Tan LYR; Shakoor SAKKA
Singapore Med J; 2022 Nov; 63(11):649-658. PubMed ID: 34602493
[TBL] [Abstract][Full Text] [Related]
12. Morphological and immunohistochemical characteristics associated with metastatic and recurrent progression in pheochromocytoma/paraganglioma: A cohort study.
Wang LL; Wei XJ; Zhang QC; Li F
Ann Diagn Pathol; 2022 Oct; 60():151981. PubMed ID: 35660808
[TBL] [Abstract][Full Text] [Related]
13. The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study.
Schovanek J; Martucci V; Wesley R; Fojo T; Del Rivero J; Huynh T; Adams K; Kebebew E; Frysak Z; Stratakis CA; Pacak K
BMC Cancer; 2014 Jul; 14():523. PubMed ID: 25048685
[TBL] [Abstract][Full Text] [Related]
14. [Clinical profile of pheochromocytoma and paraganglioma with normal plasma free metanephrines].
Liu L; Tian J; Wu K; Gao Y; Zhang Z; Zhang JQ; Guo XH
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Aug; 52(4):614-620. PubMed ID: 32773788
[TBL] [Abstract][Full Text] [Related]
15. Incidence and Clinical Presentation of Pheochromocytoma and Sympathetic Paraganglioma: A Population-based Study.
Ebbehoj A; Stochholm K; Jacobsen SF; Trolle C; Jepsen P; Robaczyk MG; Rasmussen ÅK; Feldt-Rasmussen U; Thomsen RW; Søndergaard E; Poulsen PL
J Clin Endocrinol Metab; 2021 Apr; 106(5):e2251-e2261. PubMed ID: 33479747
[TBL] [Abstract][Full Text] [Related]
16. Disease monitoring of patients with pheochromocytoma or paraganglioma by biomarkers and imaging studies.
Schreiner F; Beuschlein F
Best Pract Res Clin Endocrinol Metab; 2020 Mar; 34(2):101347. PubMed ID: 31662271
[TBL] [Abstract][Full Text] [Related]
17. Properly Collected Plasma Metanephrines Excludes PPGL After False-Positive Screening Tests.
Kline GA; Boyd J; Polzin B; Harvey A; Pasieka JL; Sadrzadeh HSM; Leung AA
J Clin Endocrinol Metab; 2021 Jul; 106(8):e2900-e2906. PubMed ID: 33846745
[TBL] [Abstract][Full Text] [Related]
18. SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma.
Assadipour Y; Sadowski SM; Alimchandani M; Quezado M; Steinberg SM; Nilubol N; Patel D; Prodanov T; Pacak K; Kebebew E
Surgery; 2017 Jan; 161(1):230-239. PubMed ID: 27839933
[TBL] [Abstract][Full Text] [Related]
19. Long-term evaluation following resection of apparently benign pheochromocytoma(s)/paraganglioma(s).
van Heerden JA; Roland CF; Carney JA; Sheps SG; Grant CS
World J Surg; 1990; 14(3):325-9. PubMed ID: 1973322
[TBL] [Abstract][Full Text] [Related]
20. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
